Paul Mischel, M.D. - Publications

Pathology University of California, San Diego, La Jolla, CA 
EGFR/PI3K/Akt/mTOR signaling network

241 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Harachi M, Masui K, Cavenee WK, Mischel PS, Shibata N. Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer. Metabolites. 11. PMID 33916219 DOI: 10.3390/metabo11040216  1
2021 Wu S, Bafna V, Mischel PS. Extrachromosomal DNA (ecDNA) in cancer pathogenesis. Current Opinion in Genetics & Development. 66: 78-82. PMID 33477016 DOI: 10.1016/j.gde.2021.01.001  1
2020 Wu S, Mischel PS. Same Script, Different Cast: Different Cell Origins Shape Molecular Features and Therapeutic Response in Glioblastoma. Cancer Cell. 38: 311-313. PMID 32931740 DOI: 10.1016/j.ccell.2020.08.012  1
2020 Luebeck J, Coruh C, Dehkordi SR, Lange JT, Turner KM, Deshpande V, Pai DA, Zhang C, Rajkumar U, Law JA, Mischel PS, Bafna V. AmpliconReconstructor integrates NGS and optical mapping to resolve the complex structures of focal amplifications. Nature Communications. 11: 4374. PMID 32873787 DOI: 10.1038/S41467-020-18099-Z  1
2020 Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, Amin SB, Yi E, Menghi F, Schulte JH, Henssen AG, ... ... Mischel PS, et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nature Genetics. PMID 32807987 DOI: 10.1038/S41588-020-0678-2  1
2020 Chiu RWK, Dutta A, Hensson AG, Lo YMD, Mischel P, Regenberg B. What Is Extrachromosomal Circular DNA and What Does It Do? Clinical Chemistry. 66: 754-759. PMID 32470125 DOI: 10.1093/Clinchem/Hvaa096  0.01
2020 Harachi M, Masui K, Honda H, Muragaki Y, Kawamata T, Cavenee WK, Mischel PS, Shibata N. Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. Molecular Cancer Research : McR. PMID 32366675 DOI: 10.1158/1541-7786.Mcr-20-0024  1
2020 Koga T, Chaim IA, Benitez JA, Markmiller S, Parisian AD, Hevner RF, Turner KM, Hessenauer FM, D'Antonio M, Nguyen ND, Saberi S, Ma J, Miki S, Boyer AD, Ravits J, ... ... Mischel PS, et al. Author Correction: Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. Nature Communications. 11: 1958. PMID 32312984 DOI: 10.1038/S41467-020-15828-2  1
2020 Bailey C, Shoura MJ, Mischel PS, Swanton C. Extrachromosomal DNA - relieving heredity constraints, accelerating tumour evolution. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32275948 DOI: 10.1016/J.Annonc.2020.03.303  0.01
2020 Masui K, Harachi M, Cavenee WK, Mischel PS, Shibata N. mTOR complex 2 is an integrator of cancer metabolism and epigenetics. Cancer Letters. PMID 32145344 DOI: 10.1016/J.Canlet.2020.03.001  1
2020 Koga T, Chaim IA, Benitez JA, Markmiller S, Parisian AD, Hevner RF, Turner KM, Hessenauer FM, D'Antonio M, Nguyen ND, Saberi S, Ma J, Miki S, Boyer AD, Ravits J, ... ... Mischel PS, et al. Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. Nature Communications. 11: 550. PMID 31992716 DOI: 10.1038/S41467-020-14312-1  1
2020 Christiansen JH, Nguyen N, Verhaak R, Kim H, Bafna V, Mischel P, Hassig C. Extrachromosomal DNA (ecDNA) carrying amplified oncogenes as a biomarker for insensitivity to pembrolizumab treatment in gastric cancer patients. Journal of Clinical Oncology. 38: 3123-3123. DOI: 10.1200/Jco.2020.38.15_Suppl.3123  1
2019 Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nature Reviews. Cancer. PMID 31806884 DOI: 10.1038/S41568-019-0226-5  1
2019 Wu S, Turner KM, Nguyen N, Raviram R, Erb M, Santini J, Luebeck J, Rajkumar U, Diao Y, Li B, Zhang W, Jameson N, Corces MR, Granja JM, Chen X, ... ... Mischel PS, et al. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature. PMID 31748743 DOI: 10.1038/S41586-019-1763-5  1
2019 Masui K, Harachi M, Ikegami S, Yang H, Onizuka H, Yong WH, Cloughesy TF, Muragaki Y, Kawamata T, Arai N, Komori T, Cavenee WK, Mischel PS, Shibata N. mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma. The Journal of Biological Chemistry. PMID 31712311 DOI: 10.1074/Jbc.Ra119.011519  1
2019 Rajkumar U, Turner K, Luebeck J, Deshpande V, Chandraker M, Mischel P, Bafna V. EcSeg: Semantic Segmentation of Metaphase Images Containing Extrachromosomal DNA. Iscience. 21: 428-435. PMID 31706138 DOI: 10.1016/J.Isci.2019.10.035  1
2019 Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, et al. Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations. Molecular Cancer Therapeutics. PMID 31575654 DOI: 10.1158/1535-7163.Mct-17-0256  1
2019 Wang X, Yang K, Wu Q, Kim LJY, Morton AR, Gimple RC, Prager BC, Shi Y, Zhou W, Bhargava S, Zhu Z, Jiang L, Tao W, Qiu Z, Zhao L, ... ... Mischel PS, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Science Translational Medicine. 11. PMID 31391321 DOI: 10.1126/Scitranslmed.Aau4972  0.01
2019 Bi J, Mischel PS. Acyl-CoA-Binding Protein Fuels Gliomagenesis. Cell Metabolism. 30: 229-230. PMID 31390546 DOI: 10.1016/j.cmet.2019.07.007  1
2019 Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, ... ... Mischel PS, et al. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nature Cell Biology. 21: 1003-1014. PMID 31371825 DOI: 10.1038/S41556-019-0363-9  1
2019 Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, ... ... Mischel PS, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism. PMID 31303424 DOI: 10.1016/J.Cmet.2019.06.014  1
2019 Gimple RC, Kidwell RL, Kim LJY, Sun T, Gromovsky AD, Wu Q, Wolf M, Lv D, Bhargava S, Jiang L, Prager BC, Wang X, Ye Q, Zhu Z, Zhang G, ... ... Mischel PS, et al. Glioma Stem Cell Specific Super Enhancer Promotes Polyunsaturated Fatty Acid Synthesis to Support EGFR Signaling. Cancer Discovery. PMID 31201181 DOI: 10.1158/2159-8290.Cd-19-0061  1
2019 Chowdhry S, Zanca C, Rajkumar U, Koga T, Diao Y, Raviram R, Liu F, Turner K, Yang H, Brunk E, Bi J, Furnari F, Bafna V, Ren B, Mischel PS. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature. PMID 31019297 DOI: 10.1038/S41586-019-1150-2  1
2019 Verhaak RGW, Bafna V, Mischel PS. Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. Nature Reviews. Cancer. PMID 30872802 DOI: 10.1038/S41568-019-0128-6  0.01
2019 Lucki NC, Villa GR, Vergani N, Bollong MJ, Beyer BA, Lee JW, Anglin JL, Spangenberg SH, Chin EN, Sharma A, Johnson K, Sander PN, Gordon P, Skirboll SL, Wurdak H, ... ... Mischel PS, et al. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30846550 DOI: 10.1073/Pnas.1816626116  1
2019 Deshpande V, Luebeck J, Nguyen ND, Bakhtiari M, Turner KM, Schwab R, Carter H, Mischel PS, Bafna V. Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. Nature Communications. 10: 392. PMID 30674876 DOI: 10.1038/S41467-018-08200-Y  1
2019 Masui K, Onizuka H, Cavenee WK, Mischel PS, Shibata N. Metabolic reprogramming in the pathogenesis of glioma: Update. Neuropathology : Official Journal of the Japanese Society of Neuropathology. PMID 30609184 DOI: 10.1111/Neup.12535  1
2018 Harachi M, Masui K, Okamura Y, Tsukui R, Mischel PS, Shibata N. mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression. International Journal of Molecular Sciences. 19. PMID 30347859 DOI: 10.3390/Ijms19103267  1
2018 Chang L, Weiner LS, Hartman SJ, Horvath S, Jeste D, Mischel PS, Kado DM. Breast cancer treatment and its effects on aging. Journal of Geriatric Oncology. PMID 30078714 DOI: 10.1016/J.Jgo.2018.07.010  1
2018 Donoghue JF, Kerr LT, Alexander NW, Greenall SA, Longano AB, Gottardo NG, Wang R, Tabar V, Adams TE, Mischel PS, Johns TG. Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response. Cancers. 10. PMID 30044378 DOI: 10.3390/Cancers10080243  0.01
2018 Bi J, Wu S, Zhang W, Mischel PS. Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context. Biochimica Et Biophysica Acta. PMID 29775654 DOI: 10.1016/j.bbcan.2018.05.002  1
2018 Nguyen ND, Deshpande V, Luebeck J, Mischel PS, Bafna V. ViFi: accurate detection of viral integration and mRNA fusion reveals indiscriminate and unregulated transcription in proximal genomic regions in cervical cancer. Nucleic Acids Research. PMID 29579309 DOI: 10.1093/Nar/Gky180  0.01
2017 Liu F, Mischel PS, Cavenee WK. Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. Npj Precision Oncology. 1: 1. PMID 29872691 DOI: 10.1038/s41698-017-0005-2  1
2017 Masui K, Kato Y, Sawada T, Mischel PS, Shibata N. Molecular and Genetic Determinants of Glioma Cell Invasion. International Journal of Molecular Sciences. 18. PMID 29207533 DOI: 10.3390/Ijms18122609  1
2017 Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, ... ... Mischel PS, et al. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 32: 856-868.e5. PMID 29198914 DOI: 10.1016/J.Ccell.2017.10.016  0.01
2017 Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nature Medicine. PMID 29035366 DOI: 10.1038/Nm.4418  1
2017 Liu F, Mischel PS. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma. Wiley Interdisciplinary Reviews. Systems Biology and Medicine. PMID 28892308 DOI: 10.1002/wsbm.1398  1
2017 Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, ... ... Mischel PS, et al. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes & Development. PMID 28724615 DOI: 10.1101/Gad.300079.117  1
2017 Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, ... ... Mischel PS, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell. PMID 28648777 DOI: 10.1016/J.Molcel.2017.05.030  1
2017 Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, ... ... Mischel PS, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. PMID 28178237 DOI: 10.1038/Nature21356  1
2016 Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, ... ... Mischel PS, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/J.Ccell.2016.09.008  1
2016 Masui K, Shibata N, Cavenee WK, Mischel PS. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 27427440 DOI: 10.1002/Bies.201600026  1
2016 Hofree M, Carter H, Kreisberg JF, Bandyopadhyay S, Mischel PS, Friend S, Ideker T. Challenges in identifying cancer genes by analysis of exome sequencing data. Nature Communications. 7: 12096. PMID 27417679 DOI: 10.1038/Ncomms12096  1
2016 Agnihotri S, Golbourn B, Huang X, Remke M, Younger S, Cairns RA, Chalil A, Smith CA, Krumholtz SL, MacKenzie D, Rakopoulos P, Ramaswamy V, Taccone MS, Mischel PS, Fuller GN, et al. PINK1 is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. Cancer Research. PMID 27325644 DOI: 10.1158/0008-5472.Can-15-3079  1
2016 Masui K, Cavenee WK, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathology. PMID 27295313 DOI: 10.1007/S10014-016-0265-5  1
2016 Villa GR, Mischel PS. Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma. Nature Neuroscience. 19: 765-7. PMID 27227363 DOI: 10.1038/nn.4302  1
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... Mischel PS, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/J.Ccell.2016.03.012  1
2016 Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handbook of Clinical Neurology. 134: 97-120. PMID 26948350 DOI: 10.1016/B978-0-12-802997-8.00006-2  1
2015 Heath JR, Ribas A, Mischel PS. Single-cell analysis tools for drug discovery and development. Nature Reviews. Drug Discovery. PMID 26669673 DOI: 10.1038/Nrd.2015.16  1
2015 Chang E, Pohling C, Natarajan A, Witney TH, Kaur J, Xu L, Gowrishankar G, L D'Souza A, Murty S, Schick S, Chen L, Wu N, Khaw P, Mischel P, Abbasi T, et al. AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models. Journal of Neuro-Oncology. PMID 26650066 DOI: 10.1007/S11060-015-1972-1  1
2015 Villa GR, Mischel PS. Shared Intelligence: A Patient-Derived, Deeply Characterized Glioblastoma Cell Line Resource. Ebiomedicine. 2: 1274-5. PMID 26629504 DOI: 10.1016/j.ebiom.2015.09.033  1
2015 Masui K, Cavenee WK, Mischel PS. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathology (Zurich, Switzerland). 25: 755-9. PMID 26526943 DOI: 10.1111/Bpa.12307  1
2015 Venneti S, Mischel PS. Metabolic Reprogramming in Brain Cancer: A Coordinated Effort. Brain Pathology (Zurich, Switzerland). 25: 753-4. PMID 26526942 DOI: 10.1111/bpa.12308  1
2015 Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, ... ... Mischel PS, et al. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell. PMID 26455392 DOI: 10.1016/J.Molcel.2015.09.002  1
2015 Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. PMID 26177599 DOI: 10.1002/Cncr.29422  1
2015 Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 26170313 DOI: 10.1073/Pnas.1511759112  1
2015 Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F. Significance of filamin A in mTORC2 function in glioblastoma. Molecular Cancer. 14: 127. PMID 26134617 DOI: 10.1186/S12943-015-0396-Z  1
2015 Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews. Cancer. 15: 302-10. PMID 25855404 DOI: 10.1038/nrc3918  1
2015 Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, ... Mischel PS, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. The Journal of Clinical Investigation. 125: 1591-602. PMID 25798620 DOI: 10.1172/Jci78239  1
2015 Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, ... ... Mischel PS, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proceedings of the National Academy of Sciences of the United States of America. 112: 1107-12. PMID 25583476 DOI: 10.1073/Pnas.1422640112  1
2015 Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Research. 75: 394-404. PMID 25432173 DOI: 10.1158/0008-5472.Can-14-2004  1
2015 Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, et al. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-Oncology. 17: 180-8. PMID 25165194 DOI: 10.1093/Neuonc/Nou154  1
2015 Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F. Significance of filamin A in mTORC2 function in glioblastoma Molecular Cancer. 14. DOI: 10.1186/s12943-015-0396-z  1
2015 Shin YS, Wei W, Gini B, Mischel P, Heath J. Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr09  1
2015 Mischel P. Abstract IA11: Targeting PI3K-mTOR signaling in glioblastoma: A central role for mTORC2 in drug resistance and metabolic reprogramming Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Ia11  0.01
2014 Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biology & Medicine. 11: 255-63. PMID 25610711 DOI: 10.7497/j.issn.2095-3941.2014.04.004  1
2014 Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, et al. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5808-22. PMID 25224277 DOI: 10.1158/1078-0432.Ccr-14-0234  1
2014 Gini B, Mischel PS. Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discovery. 4: 876-8. PMID 25092745 DOI: 10.1158/2159-8290.Cd-14-0635  1
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism: Tem. 25: 364-73. PMID 24856037 DOI: 10.1016/J.Tem.2014.04.002  1
2014 Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, ... Mischel PS, et al. Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. The Journal of Biological Chemistry. 289: 13974-85. PMID 24644285 DOI: 10.1074/Jbc.M113.543728  1
2014 Lagadec C, Vlashi E, Bhuta S, Lai C, Mischel P, Werner M, Henke M, Pajonk F. Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. Bmc Cancer. 14: 152. PMID 24593279 DOI: 10.1186/1471-2407-14-152  1
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle (Georgetown, Tex.). 13: 1053-4. PMID 24583874 DOI: 10.4161/Cc.28377  1
2014 Bernhart E, Damm S, Heffeter P, Wintersperger A, Asslaber M, Frank S, Hammer A, Strohmaier H, DeVaney T, Mrfka M, Eder H, Windpassinger C, Ireson CR, Mischel PS, Berger W, et al. Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. Neuro-Oncology. 16: 933-45. PMID 24463355 DOI: 10.1093/neuonc/not303  1
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... Mischel PS, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/Science.1241328  1
2014 Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annual Review of Pathology. 9: 1-25. PMID 23937436 DOI: 10.1146/annurev-pathol-011110-130324  1
2014 Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Current Pharmaceutical Design. 20: 2619-26. PMID 23859617 DOI: 10.2174/13816128113199990486  1
2013 Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. Plos One. 8: e80397. PMID 24260384 DOI: 10.1371/Journal.Pone.0080397  1
2013 Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, ... ... Mischel PS, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/J.Cmet.2013.09.013  1
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... Mischel PS, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.Ccr-13-0527  1
2013 Wang J, Hwang K, Braas D, Dooraghi A, Nathanson D, Campbell DO, Gu Y, Sandberg T, Mischel P, Radu C, Chatziioannou AF, Phelps ME, Christofk H, Heath JR. Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1820-4. PMID 23978446 DOI: 10.2967/Jnumed.112.118497  1
2013 Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, ... ... Mischel PS, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/J.Cmet.2013.04.013  1
2013 Mareninov S, De Jesus J, Sanchez DE, Kay AB, Wilson RW, Babic I, Chen W, Telesca D, Lou JJ, Mirsadraei L, Gardner TP, Khanlou N, Vinters HV, Shafa BB, Lai A, ... ... Mischel PS, et al. Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. Journal of Neuro-Oncology. 113: 365-73. PMID 23640138 DOI: 10.1007/S11060-013-1135-1  1
2013 Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle (Georgetown, Tex.). 12: 1473-4. PMID 23624839 DOI: 10.4161/cc.24747  1
2013 Langfelder P, Mischel PS, Horvath S. When is hub gene selection better than standard meta-analysis? Plos One. 8: e61505. PMID 23613865 DOI: 10.1371/journal.pone.0061505  1
2013 Eibinger G, Fauler G, Bernhart E, Frank S, Hammer A, Wintersperger A, Eder H, Heinemann A, Mischel PS, Malle E, Sattler W. On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment. Experimental Cell Research. 319: 1828-38. PMID 23541792 DOI: 10.1016/j.yexcr.2013.03.025  1
2013 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, ... ... Mischel PS, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.Cd-12-0502  1
2013 Wei W, Shi Q, Remacle F, Qin L, Shackelford DB, Shin YS, Mischel PS, Levine RD, Heath JR. Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 110: E1352-60. PMID 23530221 DOI: 10.1073/Pnas.1303060110  1
2013 Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. Plos Genetics. 9: e1003253. PMID 23459592 DOI: 10.1371/Journal.Pgen.1003253  1
2013 Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/Carcin/Bgt086  1
2013 Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN, Komisopoulou E, Henkin AH, Soto H, Chamberlain BT, Vergnes L, ... ... Mischel PS, et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Research. 73: 2850-62. PMID 23440422 DOI: 10.1158/0008-5472.Can-13-0382-T  1
2013 Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, ... ... Mischel PS, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/Pnas.1217602110  1
2013 Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan ?, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, ... ... Mischel PS, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics. 45: 253-61. PMID 23354438 DOI: 10.1038/Ng.2538  1
2013 Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, Shaw RJ. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 23: 143-58. PMID 23352126 DOI: 10.1016/J.Ccr.2012.12.008  1
2013 Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, ... ... Mischel PS, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology. 15: 370-81. PMID 23328811 DOI: 10.1093/Neuonc/Nos308  1
2013 Babic I, Mischel PS. Multiple functions of a glioblastoma fusion oncogene. The Journal of Clinical Investigation. 123: 548-51. PMID 23298839 DOI: 10.1172/JCI67658  1
2013 Lugassy C, Wadehra M, Li X, Corselli M, Akhavan D, Binder SW, Péault B, Cochran AJ, Mischel PS, Kleinman HK, Barnhill RL. Pilot study on "pericytic mimicry" and potential embryonic/stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 6: 19-29. PMID 23275074 DOI: 10.1007/S12307-012-0128-5  1
2013 Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. International Journal of Radiation Oncology, Biology, Physics. 85: 1206-11. PMID 23182702 DOI: 10.1016/J.Ijrobp.2012.10.008  1
2013 Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF. Probabilistic radiographic atlas of glioblastoma phenotypes. Ajnr. American Journal of Neuroradiology. 34: 533-40. PMID 22997168 DOI: 10.3174/Ajnr.A3253  1
2013 Muto J, Imai T, Ogawa D, Nishimoto Y, Okada Y, Mabuchi Y, Kawase T, Iwanami A, Mischel PS, Saya H, Yoshida K, Matsuzaki Y, Okano H. Correction: RNA-binding protein musashi1 modulates glioma cell growth through the post-transcriptional regulation of notch and PI3 kinase/akt signaling pathways (PLoS ONE) Plos One. 8. DOI: 10.1371/annotation/4c24fcf6-cf55-42f7-aa0d-3984048a2d16  1
2012 Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, ... ... Mischel PS, et al. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. Journal of the National Cancer Institute. 104: 1458-69. PMID 22945948 DOI: 10.1093/Jnci/Djs357  1
2012 Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, ... ... Mischel PS, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America. 109: 14164-9. PMID 22891331 DOI: 10.1073/Pnas.1211962109  1
2012 Babic I, Mischel PS. Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks. Cancer Discovery. 2: 676-8. PMID 22886662 DOI: 10.1158/2159-8290.CD-12-0309  1
2012 Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel PS, Graeber TG. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Molecular Systems Biology. 8: 589. PMID 22735335 DOI: 10.1038/Msb.2012.20  1
2012 Mischel PS. HOT models in flux: mitochondrial glucose oxidation fuels glioblastoma growth. Cell Metabolism. 15: 789-90. PMID 22682216 DOI: 10.1016/j.cmet.2012.05.004  1
2012 Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro-Oncology. 14: 1050-61. PMID 22670012 DOI: 10.1093/Neuonc/Nos126  1
2012 Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, ... ... Mischel PS, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery. 2: 458-71. PMID 22588883 DOI: 10.1158/2159-8290.Cd-11-0284  1
2012 Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, Manway L, Maira SM, Thorgeirsson SS, Mischel PS, Thomas G, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Science Translational Medicine. 4: 139ra84. PMID 22539746 DOI: 10.1126/Scitranslmed.3003923  1
2012 Muto J, Imai T, Ogawa D, Nishimoto Y, Okada Y, Mabuchi Y, Kawase T, Iwanami A, Mischel PS, Saya H, Yoshida K, Matsuzaki Y, Okano H. RNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of Notch and PI3 kinase/Akt signaling pathways. Plos One. 7: e33431. PMID 22428049 DOI: 10.1371/Journal.Pone.0033431  1
2012 Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/S00280-012-1854-6  1
2012 Tran LM, Chang CJ, Plaisier S, Wu S, Dang J, Mischel PS, Liao JC, Graeber TG, Wu H. Determining PTEN functional status by network component deduced transcription factor activities. Plos One. 7: e31053. PMID 22347425 DOI: 10.1371/Journal.Pone.0031053  1
2012 Qi Q, He K, Yoo MH, Chan CB, Liu X, Zhang Z, Olson JJ, Xiao G, Wang L, Mao H, Fu H, Tao H, Ramalingam SS, Sun SY, Mischel PS, et al. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. The Journal of Biological Chemistry. 287: 6113-27. PMID 22215664 DOI: 10.1074/Jbc.M111.293605  1
2012 Shi Q, Qin L, Wei W, Geng F, Fan R, Shin YS, Guo D, Hood L, Mischel PS, Heath JR. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 419-24. PMID 22203961 DOI: 10.1073/Pnas.1110865109  1
2012 Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. The Journal of Clinical Investigation. 122: 253-66. PMID 22156195 DOI: 10.1172/JCI59334  1
2012 Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology. 38: 271-91. PMID 22098029 DOI: 10.1111/J.1365-2990.2011.01238.X  1
2012 Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, Benovic JL, Piwnica-Worms D, Rubin JB. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Molecular Cancer Research : McR. 10: 156-66. PMID 22086906 DOI: 10.1158/1541-7786.Mcr-11-0411  1
2012 Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Current Topics in Microbiology and Immunology. 355: 135-69. PMID 22015553 DOI: 10.1007/82_2011_178  1
2012 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 106: 111-9. PMID 21706273 DOI: 10.1007/s11060-011-0638-x  1
2012 Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients (Journal of Clinical Investigation (2012) 122, 1, (253-266) DOI: 10.1172/JCI59334) Journal of Clinical Investigation. 122: 782. DOI: 10.1172/Jci62856  1
2012 Gini B, Guo D, Nathanson D, Shackelford D, Zhu S, Yang H, Tanaka K, Babic I, Akhavan D, Bonetti B, Mortensen D, Xu S, Raymon H, Chopra R, Mischel P. Abstract 1923: The mTOR kinase inhibitor, CC214, preferentially blocks the growth of EGFRvIII-activated glioblastomas Cancer Research. 72: 1923-1923. DOI: 10.1158/1538-7445.Am2012-1923  1
2012 Donoghue J, Kerr L, Longano A, Mischel P, Johns T. Abstract 1220: ErbB4: A novel therapeutic target in glioblastoma multiforme Cancer Research. 72: 1220-1220. DOI: 10.1158/1538-7445.Am2012-1220  0.01
2011 Lai A, Lalezari S, Chou AP, Tran A, Solis OE, Carrillo JA, Chen W, Mischel PS, Green RM, Nghiemphu PL, Liau LM, Wang H, Elashoff RM, Cloughesy TF, Yong WH. Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2003. PMID 28023883 DOI: 10.1200/Jco.2011.29.15_Suppl.2003  1
2011 Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Plos One. 6: e28973. PMID 22194965 DOI: 10.1371/Journal.Pone.0028973  1
2011 Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, ... ... Mischel PS, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.Cd-11-0124  1
2011 Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, ... ... Mischel PS, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discovery. 1: 442-56. PMID 22059152 DOI: 10.1158/2159-8290.Cd-11-0102  1
2011 Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, ... ... Mischel PS, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4482-90. PMID 22025148 DOI: 10.1200/Jco.2010.33.8715  1
2011 Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel PS, et al. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Molecular Cancer Research : McR. 9: 1668-85. PMID 22013079 DOI: 10.1158/1541-7786.Mcr-10-0563  1
2011 Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. Plos One. 6: e24217. PMID 21915300 DOI: 10.1371/Journal.Pone.0024217  1
2011 Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS, Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 16062-7. PMID 21900605 DOI: 10.1073/Pnas.1106704108  1
2011 Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science. 124: 2938-50. PMID 21878501 DOI: 10.1242/jcs.083295  1
2011 Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 1151-61. PMID 21856685 DOI: 10.1093/Neuonc/Nor079  1
2011 Mischel PS. Lost - and found - in translation. The Journal of Clinical Investigation. 121: 3357-9. PMID 21804196 DOI: 10.1172/JCI59686  1
2011 Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Journal of Translational Medicine. 9: 76. PMID 21609436 DOI: 10.1186/1479-5876-9-76  1
2011 Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro-Oncology. 13: 622-34. PMID 21558073 DOI: 10.1093/Neuonc/Nor023  1
2011 Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, Kesari S, Dirks PB, McGlade CJ, Stanford WL, Aldape K, Mischel PS, Hawkins C, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. The Journal of Experimental Medicine. 208: 689-702. PMID 21464220 DOI: 10.1084/Jem.20102099  1
2011 Kawahara H, Okada Y, Imai T, Iwanami A, Mischel PS, Okano H. Musashi1 cooperates in abnormal cell lineage protein 28 (Lin28)-mediated let-7 family microRNA biogenesis in early neural differentiation. The Journal of Biological Chemistry. 286: 16121-30. PMID 21378162 DOI: 10.1074/Jbc.M110.199166  1
2011 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 401-9. PMID 21324937 DOI: 10.1093/neuonc/noq206  1
2011 Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6-11. PMID 21208902 DOI: 10.1158/1078-0432.CCR-09-2268  1
2011 Nathanson D, Mischel PS. Charting the course across the blood-brain barrier. The Journal of Clinical Investigation. 121: 31-3. PMID 21183784 DOI: 10.1172/JCI45758  1
2011 Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 142-8. PMID 21135282 DOI: 10.1200/Jco.2010.30.2729  1
2011 Youssef M, Reinitz F, Cloughesy T, Mischel P, Guo D. Abstract C169: Inhibition of SREBPs by fatostatin reduces glioblastoma cell proliferation and viability. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C169  1
2011 Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Erratum: Genomic Landscape of Meningiomas (Brain Pathology (2010) 20 (751-762)) Brain Pathology. 21. DOI: 10.1111/J.1750-3639.2011.00503.X  1
2010 Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmacogenomics and Personalized Medicine. 3: 79-85. PMID 23226044 DOI: 10.2147/Pgpm.S7940  1
2010 Sun J, Masterman-Smith MD, Graham NA, Jiao J, Mottahedeh J, Laks DR, Ohashi M, DeJesus J, Kamei K, Lee KB, Wang H, Yu ZT, Lu YT, Hou S, Li K, ... ... Mischel PS, et al. A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Research. 70: 6128-38. PMID 20631065 DOI: 10.1158/0008-5472.Can-10-0076  1
2010 Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel PS, Moore TB, Kornblum HI. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatric Blood & Cancer. 55: 644-51. PMID 20589659 DOI: 10.1002/Pbc.22627  1
2010 Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncology. 12: 882-9. PMID 20472883 DOI: 10.1093/neuonc/noq052  1
2010 Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, ... ... Mischel PS, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. Journal of Translational Medicine. 8: 39. PMID 20406486 DOI: 10.1186/1479-5876-8-39  1
2010 Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, ... ... Mischel PS, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America. 107: 6459-64. PMID 20308550 DOI: 10.1073/Pnas.0911188107  1
2010 Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle (Georgetown, Tex.). 9: 211-2. PMID 20023392 DOI: 10.4161/Cc.9.2.10540  1
2010 Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathology (Zurich, Switzerland). 20: 751-62. PMID 20015288 DOI: 10.1111/J.1750-3639.2009.00356.X  1
2010 Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, ... Mischel PS, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics. 42: 77-82. PMID 19946270 DOI: 10.1038/Ng.491  1
2010 Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. Journal of Neuro-Oncology. 96: 359-67. PMID 19655089 DOI: 10.1007/s11060-009-9983-4  1
2009 Mischel P. A case for a science-informed perspective on health care reform. The Journal of Clinical Investigation. 119: 2855. PMID 20069712 DOI: 10.1172/Jci41038  1
2009 Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, ... ... Mischel PS, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science Signaling. 2: ra82. PMID 20009104 DOI: 10.1126/Scisignal.2000446  1
2009 Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proceedings of the National Academy of Sciences of the United States of America. 106: 19479-84. PMID 19846776 DOI: 10.1073/Pnas.0910398106  1
2009 Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel PS, Ng T, Yarden Y. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Current Biology : Cb. 19: 1788-98. PMID 19836242 DOI: 10.1016/J.Cub.2009.09.048  1
2009 Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Mischel PS, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.Can-09-0347  1
2009 Iwanami A, Cloughesy TF, Mischel PS. Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes & Development. 23: 1699-704. PMID 19651981 DOI: 10.1101/gad.1832909  1
2009 Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proceedings of the National Academy of Sciences of the United States of America. 106: 12932-7. PMID 19625624 DOI: 10.1073/Pnas.0906606106  1
2009 McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 16: 44-54. PMID 19573811 DOI: 10.1016/J.Ccr.2009.05.009  1
2009 Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 252: 182-9. PMID 19561256 DOI: 10.1148/Radiol.2521081534  1
2009 Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 500-12. PMID 19560740 DOI: 10.1016/J.Nurt.2009.04.008  1
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, ... Mischel PS, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106  1
2009 Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. Journal of Neuro-Oncology. 94: 1-19. PMID 19468690 DOI: 10.1007/s11060-009-9919-z  1
2009 Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (Dayton, Ohio). 27: 980-7. PMID 19353526 DOI: 10.1002/Stem.15  1
2009 Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 72: 1217-22. PMID 19349600 DOI: 10.1212/01.Wnl.0000345668.03039.90  1
2009 Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Research. 69: 3173-9. PMID 19318569 DOI: 10.1158/0008-5472.Can-08-3390  1
2009 Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). Journal of Neuro-Oncology. 92: 99-105. PMID 19018475 DOI: 10.1007/s11060-008-9741-z  1
2009 Mischel PS, Vanhook AM. Science signaling podcast: 15 December 2009 Science Signaling. 2: pc23. DOI: 10.1126/Scisignal.2101Pc23  1
2008 Brown PD, Krishnan S, Sarkaria J, Wu W, Mischel P, Yong WH, Arusell R, Jenkins RB, Buckner JC, Giannini C. A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2016. PMID 27948420 DOI: 10.1200/Jco.2008.26.15_Suppl.2016  1
2008 Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM, Mischel P, Yong WH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5603-9. PMID 18955445 DOI: 10.1200/Jco.2008.18.0612  1
2008 Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. Bmc Medical Genomics. 1: 52. PMID 18940004 DOI: 10.1186/1755-8794-1-52  1
2008 Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 249: 268-77. PMID 18796682 DOI: 10.1148/radiol.2491072000  1
2008 Mischel P. Paul Mischel: All about brains Journal of Cell Biology. 181: 1044-1045. PMID 18591424 DOI: 10.1083/jcb.1817pi  1
2008 de la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, Mischel PS, Louis DN, Bonni A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 5870-8. PMID 18524891 DOI: 10.1523/Jneurosci.5385-07.2008  1
2008 Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. International Journal of Radiation Oncology, Biology, Physics. 71: 1372-80. PMID 18355978 DOI: 10.1016/J.Ijrobp.2007.11.068  1
2008 Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, Dang J, Mischel PS, Baldwin WM, Fishbein MC, Kupiec-Weglinski JW, Reed EF. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. Journal of Immunology (Baltimore, Md. : 1950). 180: 2214-24. PMID 18250428 DOI: 10.4049/Jimmunol.180.4.2214  1
2008 Inge LJ, Rajasekaran SA, Yoshimoto K, Mischel PS, McBride W, Landaw E, Rajasekaran AK. Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit. Histology and Histopathology. 23: 459-67. PMID 18228203 DOI: 10.14670/Hh-23.459  1
2008 Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, ... ... Mischel PS, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 488-93. PMID 18223223 DOI: 10.1158/1078-0432.Ccr-07-1966  1
2008 Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, ... ... Mischel PS, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/Journal.Pmed.0050008  1
2008 Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, ... ... Mischel PS, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. Journal of Neuroscience Research. 86: 48-60. PMID 17722061 DOI: 10.1002/Jnr.21471  1
2008 Inge LJ, Rajasekaran SA, Yoshimoto K, Mischel PS, McBride W, Landaw E, Rajasekaran AK. Evidence for a potential tumor suppressor role for the Na,K-ATPase ß1-subunit Histology and Histopathology. 23: 459-467.  1
2008 Sun J, Ohashi M, Kamei K, Wang H, Masterman-Smith M, Yu ZTF, Kornblum HI, Mischel PS, Tseng HR. Microfluidic image cytometry (MIC) technology for in vitro molecular diagnostics 12th International Conference On Miniaturized Systems For Chemistry and Life Sciences - the Proceedings of Microtas 2008 Conference. 1108-1110.  1
2007 Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, ... ... Mischel PS, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/Pnas.0710052104  1
2007 Weaver JD, Vinters HV, Koretz B, Xiong Z, Mischel P, Kado D. Lymphomatosis cerebri presenting as rapidly progressive dementia. The Neurologist. 13: 150-3. PMID 17495760 DOI: 10.1097/01.Nrl.0000254706.85609.95  1
2007 Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2592-8. PMID 17473188 DOI: 10.1158/1078-0432.CCR-06-2772  1
2007 Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Mischel PS, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/Ng1975  1
2007 Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 378-81. PMID 17255257 DOI: 10.1158/1078-0432.CCR-06-1992  1
2007 Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine. 13: 84-8. PMID 17159987 DOI: 10.1038/Nm1517  1
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Mischel P, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/Journal.Pmed.0030485  1
2006 Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, ... ... Mischel PS, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proceedings of the National Academy of Sciences of the United States of America. 103: 17402-7. PMID 17090670 DOI: 10.1073/pnas.0608396103  1
2006 Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Molecular Cancer Research : McR. 4: 607-19. PMID 16966431 DOI: 10.1158/1541-7786.MCR-06-0005  1
2006 Mischel PS, Cloughesy T. Using molecular information to guide brain tumor therapy. Nature Clinical Practice. Neurology. 2: 232-3. PMID 16932555 DOI: 10.1038/ncpneuro0145  1
2006 Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.Can-04-4392  1
2006 Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH. HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Research. 66: 6756-62. PMID 16818651 DOI: 10.1158/0008-5472.Can-06-0185  1
2006 Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 66: 1258-60. PMID 16636248 DOI: 10.1212/01.Wnl.0000250628.10420.D8  1
2006 Carlson MR, Zhang B, Fang Z, Mischel PS, Horvath S, Nelson SF. Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks. Bmc Genomics. 7: 40. PMID 16515682 DOI: 10.1186/1471-2164-7-40  1
2006 Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Research. 66: 159-67. PMID 16397228 DOI: 10.1158/0008-5472.CAN-05-0077  1
2006 Mellinghoff IK, Cloughesy T, Mischel PS. The authors reply [5] New England Journal of Medicine. 354: 526. DOI: 10.1056/NEJMc052564  1
2005 Reardon D, Cloughesy T, Conrad C, Prados M, Xia J, Mietlowski W, Dugan M, Mischel P, Friedman H, Yung A. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3063. PMID 27945588 DOI: 10.1200/Jco.2005.23.16_Suppl.3063  1
2005 Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. Ajnr. American Journal of Neuroradiology. 26: 2466-74. PMID 16286386  1
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Mischel PS, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918  1
2005 Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5515-25. PMID 16061868 DOI: 10.1158/1078-0432.CCR-05-0464  0.48
2005 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 945-52. PMID 15937304  1
2005 Stillman BN, Mischel PS, Baum LG. New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. Brain Pathology (Zurich, Switzerland). 15: 124-32. PMID 15912884 DOI: 10.1111/J.1750-3639.2005.Tb00507.X  1
2005 Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. The Journal of Biological Chemistry. 280: 26953-64. PMID 15908427 DOI: 10.1074/jbc.M502614200  1
2005 Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Research. Molecular Brain Research. 136: 99-103. PMID 15893592 DOI: 10.1016/j.molbrainres.2005.01.017  1
2004 Yung A, Vredenburgh J, Cloughesy T, Klencke BJ, Mischel PS, Bigner DD, Aldape K, Vanderburg S, Prados M. Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1555. PMID 28015448 DOI: 10.1200/Jco.2004.22.14_Suppl.1555  1
2004 Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nature Reviews. Neuroscience. 5: 782-92. PMID 15378038 DOI: 10.1038/nrn1518  1
2004 Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. Gene expression profiling of gliomas strongly predicts survival. Cancer Research. 64: 6503-10. PMID 15374961 DOI: 10.1158/0008-5472.CAN-04-0452  1
2004 Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 23: 1283-90. PMID 14961077 DOI: 10.1038/sj.onc.1207244  1
2004 Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Laboratory Investigation; a Journal of Technical Methods and Pathology. 84: 8-20. PMID 14631378 DOI: 10.1038/Labinvest.3700003  1
2003 Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 22: 4918-23. PMID 12894235 DOI: 10.1038/sj.onc.1206753  1
2003 Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Research. 63: 2742-6. PMID 12782577  1
2003 Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 22: 2361-73. PMID 12700671 DOI: 10.1038/sj.onc.1206344  1
2003 Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathology (Zurich, Switzerland). 13: 52-61. PMID 12580545  1
2003 Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: Pathway profiling and its implications for patient therapy Cancer Biology and Therapy. 2: 242-247. DOI: 10.4161/cbt.2.3.369  1
2002 Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2894-901. PMID 12231534  1
2002 Mischel PS, Umbach JA, Eskandari S, Smith SG, Gundersen CB, Zampighi GA. Nerve growth factor signals via preexisting TrkA receptor oligomers. Biophysical Journal. 83: 968-76. PMID 12124278 DOI: 10.1016/S0006-3495(02)75222-3  1
2001 Catania MG, Mischel PS, Vinters HV. Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B. Journal of Neuropathology and Experimental Neurology. 60: 711-23. PMID 11444800 DOI: 10.1093/Jnen/60.7.711  1
2001 Mischel PS, Smith SG, Vining ER, Valletta JS, Mobley WC, Reichardt LF. The extracellular domain of p75NTR is necessary to inhibit neurotrophin-3 signaling through TrkA. The Journal of Biological Chemistry. 276: 11294-301. PMID 11150291 DOI: 10.1074/Jbc.M005132200  1
2000 Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel PS, Belldegrun A, Cloughesy TF. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurgical Focus. 9: e8. PMID 16817691 DOI: 10.3171/foc.2000.9.6.9  1
1999 Vinters HV, Park SH, Johnson MW, Mischel PS, Catania M, Kerfoot C. Cortical dysplasia, genetic abnormalities and neurocutaneous syndromes. Developmental Neuroscience. 21: 248-59. PMID 10575248 DOI: 10.1159/000017404  1
1999 Bakshi R, Mazziotta JC, Mischel PS, Jahan R, Seligson DB, Vinters HV. Lymphomatosis cerebri presenting as a rapidly progressive dementia: clinical, neuroimaging and pathologic findings. Dementia and Geriatric Cognitive Disorders. 10: 152-7. PMID 10026390 DOI: 10.1159/000017116  1
1997 Jahan R, Mischel PS, Curran JG, Peacock WJ, Shields DW, Vinters HV. Bilateral neuropathologic changes in a child with hemimegalencephaly. Pediatric Neurology. 17: 344-9. PMID 9436800 DOI: 10.1016/S0887-8994(97)00091-X  1
1996 Menchine M, Emelin JK, Mischel PS, Haag TA, Norman MG, Pepkowitz SH, Welsh CT, Townsend JJ, Vinters HV. Tissue and cell-type specific expression of the tuberous sclerosis gene, TSC2, in human tissues. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 9: 1071-80. PMID 8933518  1
1996 De Salles AA, Solberg TD, Mischel P, Massoud TF, Plasencia A, Goetsch S, De Souza E, Viñuela F. Arteriovenous malformation animal model for radiosurgery: the rete mirabile. Ajnr. American Journal of Neuroradiology. 17: 1451-8. PMID 8883640  1
1996 Vinters HV, Mischel PS, Ranchod M. Central nervous system Pathology (Philadelphia, Pa.). 3: 513-534. PMID 8795833  1
1996 Mathern GW, Babb TL, Mischel PS, Vinters HV, Pretorius JK, Leite JP, Peacock WJ. Childhood generalized and mesial temporal epilepsies demonstrate different amounts and patterns of hippocampal neuron loss and mossy fibre synaptic reorganization. Brain : a Journal of Neurology. 119: 965-87. PMID 8673505 DOI: 10.1093/Brain/119.3.965  1
1996 Kaufer D, Mendez MF, Mischel PS, Verity MA, Benson DF. Alien hand syndrome in adult onset orthochromatic leukodystrophy: Disconnection of a limb from supplementary motor areas Behavioural Neurology. 9: 5-10.  1
1995 Mischel PS, Nguyen LP, Vinters HV. Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathologic features and proposal for a grading system. Journal of Neuropathology and Experimental Neurology. 54: 137-53. PMID 7876884 DOI: 10.1097/00005072-199503000-00001  1
1995 Mischel PS, Vinters HV. Coccidioidomycosis of the central nervous system: Neuropathological and vasculopathic manifestations and clinical correlates Clinical Infectious Diseases. 20: 400-405. PMID 7742448 DOI: 10.1093/Clinids/20.2.400  1
1995 Mischel PS, Vinters HV. Neuropathology Neurosurgery Clinics of North America. 6: 565-579. PMID 7670329  1
1995 Farahani K, Mischel PS, Black KL, De Salles AAF, Anzai Y, Lufkin RB. Hyperacute thermal lesions: MR imaging evaluation of development in the brain1 Radiology. 196: 517-520. PMID 7617870  1
1995 Farrell M, Green A, Sepp T, Mischel P, Vinters H. LOSS OF HETEROZYGOSITY IN SPORADIC CORTICAL. DYSPLASIA FOR DNA MARKERS IN THE REGION OF THE TUBEROUS SCLEROSIS (TSC1) GENE ON CHROMOSOME 9q34: 11 Journal of Neuropathology and Experimental Neurology. 54: 414. DOI: 10.1097/00005072-199505000-00030  0.01
1994 McPherson SE, Kuratani JD, Cummings JL, Shih J, Mischel PS, Vinters HV. Creutzfeldt-Jakob disease with mixed transcortical aphasia: insights into echolalia. Behavioural Neurology. 7: 197-203. PMID 24487337 DOI: 10.3233/Ben-1994-73-415  1
1976 Beneking H, Mischel P, Schul G. VI-6 High Gain GaAs-Ga1-xAlxAs Heterojunction Phototransistors Ieee Transactions On Electron Devices. 23: 1263-1264. DOI: 10.1109/T-ED.1976.18640  1
1976 Beneking H, Roehle H, Mischel P, Schul G. GROWTH AND PROPERTIES OF GaP LIQUID PHASE EPITAXIAL LAYERS ON Si SUBSTRATES Inst Phys Conf Ser. 51-57.  1
1975 Schul G, Mischel P. GaxIn1-xP-GayAl1-yAs heterojunction close-confinement injection laser Applied Physics Letters. 26: 394-395. DOI: 10.1063/1.88190  1
1975 Beneking H, Grote N, Mischel P, Schul G. GROWTH AND PROPERTIES OF Ga//yAl//1// minus //yAs-Ga//xIn//1// minus //xP HETEROSTRUCTURE ELECTROLUMINESCENT DIODES . 113-120.  1
1974 Beneking H, Schul G, Mischel P, Gattung A. GaAs-GaAlAs ANTI-STOKES LIGHT CONVERTOR Electronics Letters. 10: 346-347.  1
Show low-probability matches.